AMAT Q4 Blowout Confirms AI Capex Strength, but Valuation and Export Risks Persist

What happened

Applied Materials delivered a record fiscal Q4 with revenue up 53% year over year to $10.41B and non-GAAP EPS up 92% to $4.16, confirming accelerating AI-driven semiconductor equipment demand. Full-year fiscal 2026 revenue grew 21% to $34.45B, non-GAAP EPS rose 37% to $12.89, and gross margins expanded by 130bps to 50.1%, reflecting strong pricing and mix. The company also unveiled the EPIC Center in Silicon Valley and added four new R&D partnerships, bringing total announced EPIC engagements to 15. Notably, the release does not update the two key overhangs from prior analysis: China represented about 27% of revenue in the most recent quarter and the BIS export-control settlement leaves a suspended denial order if compliance terms are breached. While these results exceed the bull-case operating assumptions, the stock still trades at roughly 47x trailing non-GAAP earnings, leaving no margin of safety.

Implication

The results reduce the probability of the bear scenario because revenue and margins are running above even the bull-case projections from the prior report. However, the valuation remains stretched with a forward P/E around 47x on fiscal 2026 non-GAAP EPS, and the market may already be pricing in sustained >30% equipment growth. The BIS export-control settlement remains a discontinuous risk: any breach of the suspended denial order would hit earnings and distribution. China exposure is still material at about 27% of revenue, and further tightening or local substitution could reverse the margin gains. Therefore, investors should wait for either a pullback toward the $500 attractive entry level or clear evidence that export-control issues are resolved before adding size.

Thesis delta

The Q4 results materially strengthen the operating bull case, with revenue growth of 53% y/y and non-GAAP EPS growth of 92% exceeding the prior report's bullish assumptions. This reduces the probability of the bear scenario, but the valuation at 47x trailing earnings and the unresolved BIS denial-order risk keep the risk/reward unattractive. The rating remains WAIT, with the re-assessment window now focused on any China regulatory developments or a valuation reset.